- Home
- AGEN vs LICN Comparison
AGEN vs LICN Comparison
Compare AGEN & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- LICN
- Stock Information
- Founded
- AGEN 1994
- LICN 2004
- Country
- AGEN United States
- LICN China
- Employees
- AGEN N/A
- LICN N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- LICN
- Sector
- AGEN Health Care
- LICN
- Exchange
- AGEN Nasdaq
- LICN Nasdaq
- Market Cap
- AGEN 96.2M
- LICN 83.8M
- IPO Year
- AGEN 2000
- LICN 2023
- Fundamental
- Price
- AGEN $2.86
- LICN $2.04
- Analyst Decision
- AGEN Buy
- LICN
- Analyst Count
- AGEN 3
- LICN 0
- Target Price
- AGEN $9.33
- LICN N/A
- AVG Volume (30 Days)
- AGEN 576.6K
- LICN 1.1M
- Earning Date
- AGEN 11-12-2024
- LICN 12-03-2024
- Dividend Yield
- AGEN N/A
- LICN N/A
- EPS Growth
- AGEN N/A
- LICN 36.90
- EPS
- AGEN N/A
- LICN 0.28
- Revenue
- AGEN $160,427,000.00
- LICN $41,929,000.00
- Revenue This Year
- AGEN N/A
- LICN N/A
- Revenue Next Year
- AGEN $0.04
- LICN N/A
- P/E Ratio
- AGEN N/A
- LICN $7.19
- Revenue Growth
- AGEN 59.00
- LICN 24.86
- 52 Week Low
- AGEN $2.50
- LICN $0.50
- 52 Week High
- AGEN $19.69
- LICN $2.44
- Technical
- Relative Strength Index (RSI)
- AGEN 28.17
- LICN 54.70
- Support Level
- AGEN $2.50
- LICN $1.70
- Resistance Level
- AGEN $2.89
- LICN $2.01
- Average True Range (ATR)
- AGEN 0.29
- LICN 0.17
- MACD
- AGEN -0.07
- LICN -0.00
- Stochastic Oscillator
- AGEN 18.75
- LICN 55.74
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About LICN Lichen China Limited
Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.